Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785785 · ClinicalTrials.gov registry record · Phase 3
A Study of Nilotinib Versus Imatinib in GIST Patients
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 644
- Enrollment target
NCT00785785 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 644 participants.
The verdict
NCT00785785, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 644 participants
- Enrollment target
Study Summary
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Interventions
- DRUG Nilotinib (AMN107)
- DRUG imatinib (STI571)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 644 participants |
| Start Date | 2009-03 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785785
The ClinicalTrials.gov registry entry for NCT00785785 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 644 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nilotinib (AMN107) is the first listed.
NCT00785785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00785785 about?
NCT00785785 is a clinical study titled "A Study of Nilotinib Versus Imatinib in GIST Patients". This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
What is the current status of trial NCT00785785?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 644 participants. The study started on 2009-03. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00785785?
The interventions under investigation include: Nilotinib (AMN107) (DRUG), imatinib (STI571) (DRUG).
Who is sponsoring clinical trial NCT00785785?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.